Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: vitamin D

Patients on Dialysis Taking Denosumab May Be at Risk of Severe Hypocalcemia

Michele B. Kaufman, PharmD, BCGP  |  December 12, 2022

The FDA is investigating the risk of severe hypocalcemia with serious outcomes, such as hospitalization and death, in patients on dialysis taking denosumab.

Filed under:Drug Updates Tagged with:denosumabdialysisDrug SafetyFDAhypocalcemiaRenal diseaseU.S. Food and Drug Administration (FDA)

To Treat or Not to Treat? The Great Debate on Treatment of Subclinical Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  December 6, 2022

PHILADELPHIA—One of the great advancements in the field of rheumatology in recent years has been the increased understanding of various stages of disease in rheumatoid arthritis (RA), including what is termed subclinical rheumatoid arthritis. However, questions remain regarding whether to treat patients with subclinical disease and whether treatment of these patients has implications in preventing…

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2022pre-rheumatoid arthritisRheumatoid arthritis

Challenging Cases in Osteoporosis: Tips from an Expert

Samantha C. Shapiro, MD  |  June 18, 2022

Using three complicated patient cases, Kenneth G. Saag, MD, MSc, shared his expertise on osteoporosis and walked through his thought process and the literature, during a session of the 2022 ACR Education Exchange.

Filed under:ConditionsEducation & TrainingMeeting ReportsOsteoarthritis and Bone DisordersOther ACR meetings Tagged with:ACR Education Exchangebisphosphonatesdenosumabeducation and trainingOsteoporosisromosozumab

Denosumab vs. Zoledronate: An Analysis of Treatments for Low Bone Mineral Density in Patients with HIV

Michele B. Kaufman, PharmD, BCGP  |  May 9, 2022

In a small study of men with low bone mineral density (BDM) living with HIV and taking anti-retroviral therapy, both zoledronate or denosumab were well tolerated and effective for bone mineral density of the lumbar spine and femoral neck.

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)denosumabHIVOsteoporosisosteoporosis treatmentszoledronate

Improving Bone Mineral Density: Risedronate vs. Denosumab

Michele B. Kaufman, PharmD, BCGP  |  March 2, 2022

Treatment with denosumab for patients with RA and glucocorticoid-induced osteoporosis led to greater increases in bone mineral density of the lumbar spine and hips of patients than treatment with risedronate.

Filed under:ACR ConvergenceConditionsDrug UpdatesMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:ACR Convergence 2021bone mineral density (BMD)denosumabGlucocorticoidsOsteoporosisrisedronate

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Jeffrey Curtis, MD, MS, MPH  |  December 7, 2021

ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RA

Case Report: Sarcoidosis in Patient with History of IgG4-Related Disease

Veronica Matto, DO, Rajshri Shah, MD, Jie Ouyang, MD, PhD, Cory Perugino, DO, & Joseph J. LaConti, MD, PhD  |  September 14, 2021

Sarcoidosis and IgG4-related disease (IgG4-RD) are both immune-mediated, often multi-organ, diseases of uncertain etiology capable of presenting with diverse clinical manifestations. Many clinical features are common to both conditions, including hypergammaglobulinemia, the ability to form inflammatory masses and involvement of the lymph nodes, lacrimal glands, salivary glands, meninges and lungs. Although imaging modalities, such as…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:IgG4 related diseaseSarcoidosis

Food & Disease: How Diet May Affect Rheumatic & Musculoskeletal Diseases

Jason Liebowitz, MD, FACR  |  July 16, 2021

Patients’ questions about pro- and anti-inflammatory diets can be challenging to address. Dr. Elena Nikiphorou provided insight into the latest research regarding the role of diet in rheumatic and musculoskeletal diseases.

Filed under:ConditionsEULAR/OtherMeeting Reports Tagged with:DietEULARfood

New Insights into CD8+ T Cells & Lupus

Lara C. Pullen, PhD  |  July 6, 2021

A recent study demonstrated that exposure to type I interferon contributes to the pathogenesis of SLE via the metabolic rewiring of CD8+ T cells, which promotes cell death.

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:CD8+ T CellsSLEsystemic lupus erythematosus (SLE)

Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis

Jason Liebowitz, MD, FACR  |  June 1, 2021

An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.

Filed under:ConditionsMeeting Reports Tagged with:ACR State-of-the-Art Clinical SymposiumheartSarcoidosisVitamin D

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 23
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences